Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

Pharmacologic therapies are the cornerstone of dermatomyositis management ... complemented by immunosuppressants or biologics in more severe or refractory cases. Advanced therapies like ...

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

NHSO approves six new drugs for insurance, enhancing treatments for tuberculosis, hepatitis C, and lymphoma, saving millions ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

To evaluate the effectiveness, safety, and target engagement of dazukibart (humanized, selective IgG1 neutralizing monoclonal antibody that targets IFNβ) in people with moderate-to-severe ...

Background: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease ... Two patients, a 5.5-year-old girl and an 11-year-old boy, were admitted with severe proximal muscle weakness and ...

Dazukibart (PF-06823859) is under development for the treatment of moderate to severe dermatomyositis, cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), chronic cutaneous ...